NEW DRUG – Lisdexamfetamine (Elvanse®)

 In Mental Health, New Product, Pharmacy Information, Simplifying Product Supply

July 2013 – Lisdexamfetamine is indicated for ADHD (attention deficit/hyperactivity disorder) in children over 6 years, where clinical response to methylphenidate has been inadequate.

Lisdexamfetamine is a pharmacologically inactive pro-drug that is converted in the blood to dexamfetaminne. Clinical response should occur within one month. Currently, the legal classification of lisdexamfetamine is prescription only medicine (POM). However, it is recommended that it should be treated as if it were a schedule 2 controlled drug as it has the action of dexamfetamine which is widely misused.

For further information:

 

http://www.medicines.org.uk/emc/medicines/27442/spc

 

Photo by Tom Varco (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons

Recent Posts

Start typing and press Enter to search

medical training seminarMedicines Optimization guidance